ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ ПРИ КАТЕТЕРНОЙ АБЛАЦИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ
Аннотация
Рассматриваются результаты рандомизированных исследований и мета-анализов, посвященных оценке эффективности и безопасности антитромботической терапии, проводимой при выполнении радиочастотной катетерной аблации у больных с фибрилляцией предсердий.
Об авторах
А. Ю. Рычков
Тюменский кардиологический научный центр, Томский национальный исследовательский медицинский центр Российской академии наук
Россия
Россия
Н. Ю. Хорькова
Тюменский кардиологический научный центр, Томский национальный исследовательский медицинский центр Российской академии наук
Россия
Россия
А. В. Минулина
Тюменский кардиологический научный центр, Томский национальный исследовательский медицинский центр Российской академии наук
Россия
Россия
Список литературы
1. Haïssaguerre M., Jaïs P., Shah D.C. et al. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation // J Cardiovasc Electrophysiol. 1996 Dec; 7(12): 1132-44.
2. Kirchhof P., Ammentorp B., Darius H. et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREventionoFthromboemolic events - European Registry in Atrial Fibrillation (PREFER in AF) // Europace. 2014; 16: 6-14.
3. Calkins H., Reynolds M.R., Spector P. et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses // Circ Arrhythm Electrophysiol. 2009; 2: 349-361.
4. Cappato R., Calkins H., Chen S.A. et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation // Circ Arrhythm Electrophysiol. 2010; 3: 32-38.
5. Lee G., Sparks P.B., Morton J. et al. Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center // J Cardiovasc Electrophysiol 2011; 22: 163-168.
6. Calkins H., Kuck K.H., Cappato R. et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation // Heart Rhythm. 2012. Apr; 9(4): 632-696.
7. Ревишвили А.Ш., Бойцов С.А., Давтян К.В. и др. Клинические рекомендации по проведению электро-физиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. М. - 2017, 704 с.
8. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS // European Heart Journal. 2016. 37, 2893-2962.
9. Nairooz R., Sardar P., Pino M. et al. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation. International Journal of Cardiology. 2015. 187, 345-353
10. Di Biase L., Burkhardt J.D., Santangeli P. et al. Peri-procedural Stroke and Bleeding Complications inPatients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management: Results From the Role of Coumadin in PreventingThromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Randomized Trial // Circulation. 2014 Jun 24; 129(25): 2638-44.
11. Di Biase L., Burkhardt J.D., Santangeli P. et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial // Circulation 2014. 129, 2638-2644.
12. Cappato R., Ezekowitz M.D., Klein A.L. et al. Rivar-oxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation // Eur. Heart J. 2014. 35, 3346-3355.
13. Cappato R., Marchlinski F.E., Hohnloser S.H. et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015 Jul 21; 36(28): 1805-11.
14. Providência R., Albenque J.P., Combes S. et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis // Heart. 2014 Feb; 100(4): 324-35.
15. Sardar P., Nairooz R., Chatterjee S. et al. Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation // Am J Cardiol. 2014 Apr 1; 113(7): 1173-7.
16. Calkins H., Willems S., Gerstenfeld E.P. et al. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation // N Engl J Med. 2017 Apr 27; 376(17): 1627 -1636.
17. Ukaigwe A., Shrestha P., Karmacharya P. et al. Metaanalysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation // J Interv Card Electrophysiol. 2017 Mar; 48(2): 223-233.
18. DiBiase L., Callans D., Hæusler K.G. et al. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multicentre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. // Europace. 2017 Jan; 19(1): 132-138.
19. Cappato R., Ezekowitz M.D., Klein A.L. et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. // Eur Heart J. 2014 Dec 14; 35(47): 3346-55.
20. Lip G.Y., Hammerstingl C., Marin F. et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). // Am Heart J. 2016 Aug; 178: 126-34.
Рецензия
Для цитирования:
Рычков А.Ю., Хорькова Н.Ю., Минулина А.В. ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ ПРИ КАТЕТЕРНОЙ АБЛАЦИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ. Вестник аритмологии. 2017;(90):70-73.
For citation:
Rychkov A.Yu., Khorkova N.Yu., Minulina A.V. ORAL ANTICOAGULANTS DURING CATHETER ABLATION OF ATRIAL FIBRILLATION. Journal of Arrhythmology. 2017;(90):70-73. (In Russ.)
Просмотров:
141
Послать статью по эл. почте 